When Biogen Inc. (NASDAQ: BIIB) reported its first-quarter financial results before the markets opened on Wednesday, the firm said that it had $9.14 in earnings per share (EPS) and $3.53 billion in revenue. Analysts were calling for $7.73 in EPS and revenue $3.41 billion. The same period of last year reportedly had EPS of $6.98 on $3.39 billion in revenue.
Concerning the COVID-19 pandemic, Biogen estimates that its first-quarter product revenues benefitted by approximately $100 million, attributed to accelerated sales as a result, primarily in Europe.
[in-text-ad]
In terms of its segments, the company reported as follows:
- Multiple sclerosis (MS) revenues, including $162 million in royalties on the sales of Ocrevus, increased 9% versus the prior year to $2,280 million.
- Spinraza revenues increased 9% versus the prior year to $565 million.
- Biosimilars revenues increased 25% versus the prior year to $219 million.
- Other revenues decreased 63% versus the prior year to $109 million primarily due to the sale of approximately $200 million of hemophilia inventory to Bioverativ in the first quarter of 2019.
At the end of the quarter, Biogen had cash, cash equivalents and marketable securities totaling approximately $4.83 billion and approximately $5.96 billion in notes payable.
Biogen did not issue guidance for the second quarter. However, analysts are calling for $8.28 in EPS and $3.54 billion in revenue. Looking ahead to the full year, analysts are forecasting $32.29 in EPS and $14.06 billion in revenue.
Michel Vounatsos, Biogen’s CEO, commented:
The COVID-19 pandemic has created a challenging situation for people and companies throughout the world, and Biogen personally felt the painful impact of this global crisis. During these challenging and unprecedented times, Biogen has continued to deliver on its mission and purpose. We have continued to operate our business and deliver our therapies to patients across the world and are especially grateful to our dedicated employees as we continue to execute on our strategy.
Biogen stock traded down about 11% to $293.77 on Wednesday, in a 52-week range of $215.78 to $374.99. The consensus price target is $331.69.
The Average American Has No Idea How Much Money You Can Make Today (Sponsor)
The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.
But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.
Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.